Abstract
Resistance to an anthracycline-based regimen, such as CHOP, constitutes a problem for curing non-Hodgkin's lymphoma (NHL) patients. Chemoresistance in the clinic manifests itself as a lack of response to treatment or regrowth of a tumour after an initial response. In this study, lymphocytes from NHL patients were treated with hydrogen peroxide (H(2)O(2)), a free radical generating model agent, and ethyl methanesulfonate (EMS), a model alkylating agent, to induce DNA damage which was evaluated by SCGE. This study assessed whether or not there were any differences in the patterns of damage and repair between cells from patients with p53 mutant protein abnormalities, i.e. over-expression (p53(+)) not responding to the CHOP regimen and patients responding to the CHOP regimen without p53 protein abnormalities (p53(-)) by comparison with control individuals (wild-type). An NHL cell line model [Raji TK(+) (mex(+)) and TK(-) (mex(-))] with p53 over-expression was also investigated. Results showed that frozen/thawed samples from healthy people were not suitable for use in repair studies, whilst fresh samples or samples incubated for 20 h at room temperature could be used. Tumour cells were more sensitive to damage than control cells. Af...Continue Reading
References
Oct 1, 1991·Molecular and Cellular Biology·T TrigliaA F Cowman
Feb 1, 1991·Mutation Research·G H Strauss
Feb 1, 1988·Trends in Pharmacological Sciences·M M Gottesman, I Pastan
Mar 1, 1988·Experimental Cell Research·N P SinghE L Schneider
Aug 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·P Karran
May 1, 1985·Carcinogenesis·P Karran, S A Williams
Apr 8, 1993·The New England Journal of Medicine·R I FisherT P Miller
Jan 1, 1995·Environmental and Molecular Mutagenesis·A HartmannG Speit
Oct 1, 1993·Environmental Health Perspectives·R J AlbertiniJ P O'Neill
Oct 28, 1993·The New England Journal of Medicine·C C Harris, M Hollstein
Jan 1, 1996·Environmental and Molecular Mutagenesis·S Pfuhler, H U Wolf
May 1, 1996·Genes & Development·L J Ko, C Prives
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Lehnert
Feb 1, 1996·Current Opinion in Genetics & Development·S Bates, K H Vousden
Jan 31, 1997·Mutation Research·E E VisvardisS M Piperakis
Jan 1, 1997·Current Opinion in Oncology·W S el-Deiry
Jun 25, 1998·Leukemia & Lymphoma·S NavaratnamJ B Johnston
Mar 29, 2000·Environmental and Molecular Mutagenesis·R R TiceY F Sasaki
Jun 6, 2000·Mutation Research·F KassieS Knasmüller
Jul 29, 2000·Mutation Research·R J AlbertiniA Aitio
Sep 7, 2000·Current Opinion in Oncology·B TanL Ratner
Jul 9, 2002·Scandinavian Journal of Immunology·A BøyumD Løvhaug
Oct 18, 2002·Histopathology·M B MøllerN T Pedersen
Jan 6, 2006·Human Mutation·Ewy MathePierre Hainaut
Citations
Dec 15, 2015·Molecular Cancer·Rosalba CamiciaPaul O Hassa
Feb 2, 2008·The Journal of Pharmacy and Pharmacology·Song-Qiang XieBian-Sheng Ji
Mar 5, 2011·Molecular Carcinogenesis·Claudia M MonroyRanda El-Zein
Sep 14, 2011·PloS One·Liang-Chuan LaiEric Y Chuang
Oct 17, 2012·PloS One·Winnie S LiangDaniel Von Hoff
Jul 28, 2006·Journal of Pharmacological and Toxicological Methods·Behzad ForoutanDiana Anderson
Dec 12, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Xiang WangQing Mao
Dec 8, 2016·JMIR Research Protocols·Ntsikelelo PefileSaloshni Naidoo
Aug 30, 2013·Experimental Biology and Medicine·Steve A Maxwell, Seyed Mousavi-Fard